Clinical Trials | March 11, 2026
Pfizer’s experimental atopic dermatitis drug shows strong Phase 2 results
The study hit its primary goal, showing a statistically significant rise in participants achieving EASI-75
The study hit its primary goal, showing a statistically significant rise in participants achieving EASI-75
Under the deal, Hims & Hers will offer patients access to FDA-approved versions of Ozempic and Wegovy at the same self-pay prices available through other telehealth platforms
The results, published in The Lancet, showed orforglipron delivered significantly greater reductions in both A1C and body weight across primary and key secondary endpoints
The company said the move applies to all doses and reflects its commitment to making its medicines more affordable for patients
Zydus has developed an innovative Semaglutide Injection (15 mg/3 ml) in a prefilled cartridge administered using a patient-friendly reusable pen for which the company has exclusive rights
The product will target Type 2 diabetes management aligning with unmet needs in India’s expanding metabolic care landscape
UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies
The approval is based on the SWIFT and ANCHOR phase III trials, which demonstrated sustained efficacy with a twice-yearly dosing regimen
Semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus
Semaglutide—a glucagon?like peptide?1 receptor agonist (GLP-1RA) sold as Ozempic and Rybelsus for type 2 diabetes, and Wegovy for weight management and cardiovascular risk reduction
Subscribe To Our Newsletter & Stay Updated
